Contact Us

These non-promotional scientific presentations were presented at the medical congresses referenced below and are intended for U.S healthcare professionals who were in attendance for the purposes of scientific exchange.

These materials may contain information outside of the FDA approved label or relate to uses that have not been approved by the FDA. Syndax does not recommend use of Syndax products in any manner other than as described in the FDA-approved Prescribing Information.

European Hematology Association Annual Congress 2025

Milan, Italy June 12 - 15, 2025

Results 11

Oral Presentation | Jun 12, 2025

Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed Older Adults with Acute Myeloid Leukemia (AML) and NPM1 mutation or KMT2A rearrangement: Updated Results from the Beat AML Consortium

Zeidner JF, et al.

View Material

Poster Presentation | Jun 12, 2025

Revumenib Activity in Patients with NUP98r Acute Leukemia: Results from the AUGMENT-101 Phase 1 Study

Issa GC, et al.

View Material

Poster Presentation | Jun 12, 2025

Updated Results and Longer Follow-Up From the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia

Aldoss I, et al.

View Material

Poster Presentation | Jun 12, 2025

Patients With Relapsed or Refractory (R/R) Nucleophosmin 1–Mutated (NPM1m) Acute Myeloid Leukemia (AML): Updated Results from the Phase 2 AUGMENT-101 Study

Arellano ML, et al.

View Material

Abstract | Jun 12, 2025

Trial in Progress: A Phase 1 Study of Revumenib + Intensive Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia Harboring Genetic Alterations in KMT2A, NPM1, or NUP98 (SNDX-5613-0708)

Aldoss I, et al.

View Material

Abstract | Jun 12, 2025

Treatment Patterns in Patients with Relapsed or Refractory NPM1 Mutated (NPM1m) Acute Myeloid Leukemia (AML) in the United States (US): Real-world Data Analysis

Gahlon G, et al.

View Material

Poster Presentation | Jun 12, 2025

Inhibition of CSF1R-CSF1 Axis with Axatilimab Effectively Targets Leukemia Stem Cells and Monocytes in BH3 Mimetics-Resistant AML

Carter BZ, et al.

View Material

Poster Presentation | Jun 12, 2025

Trial in Progress: A Randomized, Open-Label, Phase 3 Study of Axatilimab Versus Best Available Therapy in Patients With Chronic Graft-Versus-Host Disease After ≥2 Prior Lines of Systemic Therapy

Kwon M, et al.

View Material

Poster Presentation | Jun 12, 2025

Correlations of Clinician-Reported Responses With Other Response Measures in Patients With Chronic Graft-Versus-Host Disease: An Analysis From the AGAVE-201 Trial

Pidala J, et al.

View Material